Clinical Trial Update: Personalized NK Cell Therapy in CBT [Phase 2]

View source ↗

Summary

A Phase 2 trial from MD Anderson is evaluating personalized NK cell therapy across several hematologic cancers. The study is currently recruiting, and condition…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Personalized NK Cell Therapy

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Status: RECRUITING